XML 42 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation and Benefit Plans
12 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation and Benefit Plans Stock-Based Compensation and Benefit Plans
Stock incentive plans
The purpose of our stock incentive plans is to attract, retain and motivate eligible persons whose present and potential contributions are important to our success by offering them an opportunity to participate in our future performance through equity awards. We have one primary stock incentive plan: the 2013 Equity Incentive Plan (the 2013 Plan), under which incentive stock options may be granted only to employees (including officers and directors who are also employees), and other awards may be granted to employees, officers, directors, consultants, independent contractors, and advisors. As amended, our stockholders have approved and reserved 82 million shares of common stock for issuance under the 2013 Plan. Stock options granted under the 2013 Plan expire no more than 10 years from the date of grant.
In connection with the Merger, we assumed the outstanding equity awards under two of Avast’s equity incentive plans (the Avast Holding B.V. 2014 Share Option Plan and the Rules of the Avast plc Long Term Incentive Plan (collectively, the Avast Plans)), which consisted of $4 million unvested RSUs. The assumed RSUs generally retain the terms and conditions under which they were originally granted. We intend to grant all additional shares that remain available for issuance under the Avast Plans. Upon vesting, these assumed RSUs and any additional shares granted will settle into shares of our common stock. See Note 4 for further information about this business combination.
As of March 31, 2023, 9 million shares remained available for future grant, calculated using the maximum potential shares that could be earned and issued at vesting.
RSUs
(In millions, except per share and year data)Number of
Shares
Weighted-
Average
Grant Date Fair Value
Outstanding as of April 1, 2022$21.80 
Granted$22.38 
Vested(3)$21.12 
Forfeited(1)$22.38 
Outstanding as of March 31, 2023$22.45 
RSUs generally vest over a three-year period. The weighted-average grant date fair value per share of RSUs granted during fiscal 2023, 2022 and 2021 was $22.38, $22.53, and $20.70, respectively. The total fair value of RSUs released in fiscal 2023, 2022 and 2021 was $74 million, $57 million, and $86 million, respectively, which represents the market value of our common stock on the date the RSUs were released.
PRUs
(In millions, except per share and year data)Number of
Shares
Weighted-
Average
Grant Date Fair Value
Outstanding and unvested as of April 1, 2022$28.50 
Granted$27.07 
Vested (1)
— $31.75 
Forfeited(1)$26.70 
Unvested at March 31, 2023$28.01 
Vested and unreleased as of March 31, 2023
Outstanding as of March 31, 2023
(1) The number of shares is less than 1 million.
The total fair value of PRUs released in fiscal 2023, 2022 and 2021 was $5 million, $0 million, and $43 million, respectively, which represents the market value of our common stock on the date the PRUs were released.
We have granted PRUs to certain of our executives. Typically, these PRUs have a three-year vest period. PRUs granted in fiscal 2023, 2022 and 2021 contain a combination of our company’s performance and market conditions. The performance conditions are based on the achievement of specified two-year non-GAAP financial metrics. The market conditions are based on the achievement of our relative total shareholder return over a three- and five-year period. Typically, 0% to 200% of target shares are eligible to be earned based on the achievement of the performance and market conditions.
Valuation of PRUs
The fair value of each PRU that does not contain a market condition is equal to the market value of our common stock on the date of grant. The fair value of each PRU that contains a market condition is estimated using the Monte Carlo simulation model. The valuation and the underlying weighted-average assumptions for PRUs are summarized below:
 Year Ended
March 31, 2023April 1, 2022April 2, 2021
Expected term3.3 years3.9 years2.7 years
Expected volatility34.8 %37.6 %42.5 %
Risk-free interest rate3.4 %1.0 %0.2 %
Expected dividend yield1.3 %— %— %
Weighted-average grant date fair value of PRUs$27.07$28.68$26.39
Stock options
(In millions, except per share and year data)Number of
Shares
Weighted-Average Exercise PriceWeighted-
Average
Remaining Contractual Term
(Years)
Aggregate Intrinsic
Value
Outstanding as of April 1, 2022 (1)
— $5.51 
Exercised (1)
— $4.43 
Forfeited and expired (1)
— $2.58 
Outstanding as of March 31, 2023 (1)
— $5.97 
Exercisable as of March 31, 2023 (1)
— $5.97 3.84$
(1) The number of shares is less than 1 million.
The total intrinsic value of options exercised during fiscal 2023, 2022 and 2021 was $1 million, $3 million, and $18 million, respectively. No options were granted in fiscal 2023, 2022 and 2021.
ESPP
Under our 2008 Employee Stock Purchase Plan, employees may annually contribute up to 10% of their gross compensation, subject to certain limitations, to purchase shares of our common stock at a discounted price. Eligible employees are offered shares through a 12-month offering period, which consists of two consecutive 6-month purchase periods, at 85% of the lower of either the fair market value on the purchase date or the fair market value at the beginning of the offering period.
As of March 31, 2023, 39 million shares have been issued under this plan, and 31 million shares remained available for future issuance.
The following table summarizes activity related to the purchase rights issued under the ESPP:
 Year Ended
(In millions)March 31, 2023April 1, 2022April 2, 2021
Shares issued under the ESPP
Proceeds from issuance of shares$12 $13 $14 
The fair value of each stock purchase right under our ESPP is estimated using the Black-Scholes option pricing model. The weighted-average grant date fair value related to rights to acquire shares of common stock under our ESPP in fiscal 2023, 2022 and 2021 was $6.04 per share, $6.77 per share, and $5.65 per share, respectively.
Dividend equivalent rights (DERs)
Our RSUs and PRUs, except for the $4 million unvested RSUs assumed under the Avast Plans, contain DERs that entitles the recipient of an award to receive cash dividend payments when the associated award is released. The amount of DER equals to the cumulated dividends on the issued number of common stock that would have been payable since the date the associated award was granted. As of March 31, 2023 and April 1, 2022, current dividends payable related to DER was $5 million and $11 million, respectively, recorded as part of Other current liabilities in the Consolidated Balance Sheets, and long-term dividends payable related to DER was $2 million and $2 million, respectively, recorded as part of Other long-term liabilities.
Stock-based award modifications
In connection with the Broadcom sale, during fiscal 2021 and 2020, we entered into severance and retention arrangements with certain executives. Pursuant to these agreements, these executives were entitled to receive vesting of 50% of their unvested equity, subject to a service condition, and the remaining unvested equity will be earned at levels of 0% to 150%, subject to market and service conditions. In addition, we entered into severance and retention arrangements with certain other employees in connection with restructuring activities and the Broadcom sale, which accelerated either a portion or all of the vesting of their stock-based awards. All award modifications related to the Broadcom sale were fully expensed by fiscal 2021.
The following table summarizes the stock-based compensation expense recognized as a result of these modifications:
Year Ended
(In millions)
April 2, 2021
Sales and marketing$
Research and development
General and administrative
Restructuring and other costs10 
Discontinued operations
Total stock-based compensation$30 
Stock-based compensation expense
Total stock-based compensation expense and the related income tax benefit recognized for all of our equity incentive plans in our Consolidated Statements of Operations were as follows:
 Year Ended
(In millions)March 31, 2023April 1, 2022April 2, 2021
Cost of revenues$$$
Sales and marketing34 19 18 
Research and development31 19 26 
General and administrative55 30 26 
Restructuring and other costs11 — 10 
Other income (expense), net— — (1)
Total stock-based compensation from continuing operations134 70 80 
Discontinued operations— — 
Total stock-based compensation expense$134 $70 $81 
Income tax benefit for stock-based compensation expense$(20)$(11)$(18)
As of March 31, 2023, the total unrecognized stock-based compensation expense related to our unvested stock-based awards was $226 million, which will be recognized over an estimated weighted-average amortization period of 2.0 years.
Other employee benefit plans
401(k) plan
We maintain a salary deferral 401(k) plan for all of our U.S. employees. This plan allows employees to contribute their pretax salary up to the maximum dollar limitation prescribed by the Internal Revenue Code. We match the first 3.5% of a participant’s eligible compensation up to $6,000 in a calendar year. Our employer matching contributions to the 401(k) plan were as follows, including contributions to employees of our discontinued operations:
 Year Ended
(In millions)March 31, 2023April 1, 2022April 2, 2021
401(k) matching contributions$$$